Safer dialysis for bleeding patients? citrate vs. heparin tested

NCT ID NCT03562754

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested two ways to prevent blood clots during dialysis in 60 patients at high risk of bleeding. One method used a special blood thinner called citrate, the other used a low dose of standard heparin. The goal was to see which approach allowed dialysis to run longer and more safely. Results could help doctors choose the best option for fragile patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: citrate (regional citrate anticoagulation) versus low-dose heparin
What this could lead to: If successful, this could show that citrate is a safer blood-thinner option during dialysis for patients at risk of bleeding.
What could go wrong: This is a small, single-center trial with only 60 participants, so results may not apply broadly. Both methods have risks like clotting or metabolic issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS

Contacts and locations

Locations

CHU Nimes

Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.